RxDoctor Payments Data

Kimberly Hoste

Family · Mesa, AZNPI 1285245969

Payments from drug & device makers

$2,156in general payments, 2019–2025

Across 121 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$354
  • Lilly USA, LLC$317
  • Novo Nordisk$240
  • Amgen$126
  • Bayer$122
  • Exact Sciences$112
  • plus $885 from 26 others

What the payments were for

  • Food & beverage$2,156100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,156 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$59,304
Medicare patients
210
Services billed
1,371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$86,909
EliquisApixaban27$40,855
UbrelvyUbrogepant12$20,542
RybelsusSemaglutide12$16,551
JardianceEmpagliflozin16$16,410
FarxigaDapagliflozin Propanediol12$9,276
Butorphanol Tartrate16$2,727
Atorvastatin Calcium132$1,588
Albuterol Sulfate HfaAlbuterol Sulfate48$1,396
Fenofibrate27$1,291
Levothyroxine Sodium136$1,244
Venlafaxine Hcl ErVenlafaxine Hcl42$1,216
Omeprazole60$1,076
Ondansetron OdtOndansetron70$1,047
Pantoprazole Sodium74$1,046

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$240$103,46088 claims
PfizerEliquis$86$40,85527 claims
AbbVieUbrelvy, Armour Thyroid$354$21,52029 claims
Boehringer IngelheimJardiance$59$16,41016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.

Other family in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →